Key facts
- This page summarizes John Celebi's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2025, 18:03.
John Celebi - 14 Feb 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)
- Reporting relationship
- PRESIDENT AND CEO, Director
- Issuer ticker
- SNSE
- Reported as of
- 14 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2025, 18:03:39 UTC
- Prior SEC filing
- 23 Dec 2024
- Next SEC filing
- 26 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Celebi filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 14 Feb 2025.
Change
- Previous filing in this sequence was filed on 23 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNSE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +360,000
- Change %
- Price
- $0.000000
- Shares after
- 360,000
- Date
- 14 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 360,000
- Exercise price
- $0.4760
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.